See more : Invesco Mortgage Capital Inc. (IVR) Income Statement Analysis – Financial Results
Complete financial analysis of Pharnext SA (ALPHA.PA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Pharnext SA, a leading company in the Biotechnology industry within the Healthcare sector.
- Harrisons Malayalam Limited (HARRMALAYA.NS) Income Statement Analysis – Financial Results
- Parabellum Acquisition Corp. Re (PRBM-WT) Income Statement Analysis – Financial Results
- Brighter AB (publ) (BRIG.ST) Income Statement Analysis – Financial Results
- Intact Gold Corp. (ITTGF) Income Statement Analysis – Financial Results
- Loop Telecommunication International,Inc. (3025.TW) Income Statement Analysis – Financial Results
Pharnext SA (ALPHA.PA)
About Pharnext SA
Pharnext SA, a clinical-stage biopharmaceutical company, develops therapies for orphan and common neurodegenerative diseases in France. The company's products include SYNGILITY that has completed Phase III trial for the treatment of Charcot-Marie-Tooth disease type 1A; and PXT864, which has completed Phase II clinical trial to treat Alzheimer's disease, as well as Parkinson's disease and amyotrophic lateral sclerosis. It also develops PLEOTHERAPY, a big genetic data and artificial intelligence platform. Pharnext SA has an agreement with the University Hospital Institute Mediterranee Infection to evaluate repurposed drugs for potential use against the COVID-19 virus. The company was founded in 2007 and is headquartered in Issy-Les-Moulineaux, France.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 10.00K | 558.00 | 84.79K | 39.83K | 252.77K | 6.83M | 3.32M | 4.42M | 2.63M | 2.76M | 2.63M |
| Cost of Revenue | 19.35M | -2.26M | -3.48M | 324.55K | 604.86K | 670.61K | 115.83K | 68.25K | 755.39K | 661.67K | 530.40K |
| Gross Profit | -19.34M | 2.26M | 3.56M | -284.72K | -352.09K | 6.16M | 3.21M | 4.35M | 1.88M | 2.10M | 2.10M |
| Gross Profit Ratio | -193,388.50% | 404,643.19% | 4,204.46% | -714.84% | -139.29% | 90.18% | 96.51% | 98.46% | 71.29% | 76.00% | 79.87% |
| Research & Development | 0.00 | 20.57M | 19.13M | 12.66M | 14.92M | 17.66M | 15.53M | 13.59M | 7.65M | 6.72M | 8.74M |
| General & Administrative | 0.00 | 7.41M | 4.70M | 6.07M | 4.99M | 4.31M | 5.95M | 4.17M | 3.60M | 2.33M | 1.40M |
| Selling & Marketing | 0.00 | 2.09M | 2.07M | 2.09M | 3.45M | 2.76M | -115.83K | -4.91K | 0.00 | 0.00 | 0.00 |
| SG&A | 41.77M | 8.83M | 6.05M | 7.69M | 8.17M | 7.07M | 5.83M | 4.17M | 3.60M | 2.33M | 1.40M |
| Other Expenses | -17.87M | -9.66K | -43.48K | -8.23K | -3.38K | -3.34K | -5.22K | 465.68K | 1.00 | -1.23M | -1.32M |
| Operating Expenses | 23.90M | 29.41M | 25.22M | 20.36M | 23.10M | 25.30M | 21.37M | 17.29M | 12.57M | 7.82M | 8.82M |
| Cost & Expenses | 23.90M | 30.08M | 26.42M | 21.72M | 23.62M | 25.30M | 21.48M | 17.36M | 12.57M | 7.82M | 8.82M |
| Interest Income | 0.00 | 627.64K | 4.63K | 10.02K | 7.25K | 2.84M | 1.23M | 1.81M | 1.05M | 87.36K | 190.36K |
| Interest Expense | 2.60M | 769.23K | 2.99M | 2.21M | 3.14M | 3.00M | 3.33M | 2.18M | 2.36M | 1.30M | 91.97K |
| Depreciation & Amortization | -108.82K | 669.98K | 1.21M | 1.37M | 524.73K | 152.97K | 115.83K | 68.25K | 50.57K | 39.69K | 164.31K |
| EBITDA | -25.70M | -27.97M | -29.65M | -18.17M | -19.85M | -17.82M | -20.72M | -19.07M | -8.58M | -9.26M | -9.07M |
| EBITDA Ratio | -257,040.89% | -5,269,779.57% | -29,640.23% | -51,010.90% | -9,037.83% | -260.90% | -643.29% | -391.11% | -326.06% | -326.11% | -334.22% |
| Operating Income | -23.89M | -30.08M | -26.34M | -21.68M | -23.37M | -17.91M | -21.48M | -17.36M | -8.63M | -7.82M | -8.81M |
| Operating Income Ratio | -238,875.82% | -5,389,847.67% | -31,063.10% | -54,441.83% | -9,245.42% | -262.23% | -646.78% | -392.66% | -327.99% | -283.64% | -334.56% |
| Total Other Income/Expenses | -4.42M | -1.81M | -10.98M | -5.25M | -3.10M | -3.41M | -2.69M | -3.95M | -2.36M | -2.91M | -507.94K |
| Income Before Tax | -28.30M | -40.36M | -33.84M | -24.17M | -26.47M | -21.32M | -24.17M | -21.31M | -10.99M | -10.73M | -9.32M |
| Income Before Tax Ratio | -283,026.96% | -7,232,910.04% | -39,914.41% | -60,672.82% | -10,473.51% | -312.15% | -727.62% | -482.04% | -417.82% | -389.21% | -353.84% |
| Income Tax Expense | -785.28K | -1.91M | -3.22M | -2.60M | -3.17M | -3.86M | -3.92M | -3.86M | 0.00 | 404.39K | 260.63K |
| Net Income | -27.52M | -38.45M | -30.62M | -21.56M | -23.31M | -21.32M | -20.24M | -17.45M | -10.99M | -10.73M | -9.32M |
| Net Income Ratio | -275,174.20% | -6,889,946.95% | -36,112.10% | -54,140.26% | -9,221.38% | -312.15% | -609.56% | -394.64% | -417.82% | -389.21% | -353.84% |
| EPS | -196.55 | -10.41K | -10.07K | -5.56K | -7.64K | -8.82K | -5,000,000.00B | -5,000,000.00B | -10.99M | -10.73M | -9.32M |
| EPS Diluted | -196.55 | -10.41K | -10.07K | -5.56K | -7.64K | -8.82K | -5,000,000.00B | -5,000,000.00B | -10.99M | -10.73M | -9.32M |
| Weighted Avg Shares Out | 140.00K | 3.69K | 3.04K | 3.88K | 3.05K | 2.42K | 0.00 | 0.00 | 1.00 | 1.00 | 1.00 |
| Weighted Avg Shares Out (Dil) | 140.00K | 3.69K | 3.04K | 3.88K | 3.05K | 2.42K | 0.00 | 0.00 | 1.00 | 1.00 | 1.00 |
Source: https://incomestatements.info
Category: Stock Reports